Roche Subsidiary Genentech Inks $570 Million Deal with Starpharma to Develop Novel Dendrimer-Enhanced Oncology Therapies

September 22, 2025, Australian biotechnology companyStarpharmaAnnounce, withGenentech, a member of the Roche GroupSign a cooperation and licensing agreement, both parties will utilize Starpharma's proprietary DEP® (dendrimer-enhanced product) drug delivery technology,Jointly develop a series of new cancer therapies.

• According to the agreement,Genentech to Obtain Global Exclusive License from Starpharma for DEP® Platform, to integrate its existing anticancer drugs for the development and commercialization of dendrimer drug conjugates targeting certain tumor markers.

• In return, Starpharma will receive a payment$5.5 millionThe upfront payment and is eligible to receive up to$564 millionThe development, commercialization, and net sales milestone payments. In addition, Starpharma will also receive royalties based on a tiered structure for the global net sales generated from the collaboration.

DEP® Platform is a proprietary drug delivery technology based on dendrimers, which can enhance the efficacy, safety, and targeted delivery capability of drugs. The technology offers high flexibility in drug formulation, applicable to small molecule drugs, peptides, proteins, and nucleic acid-based drugs, while also providing more possibilities for combination therapies and the development of broader cancer indications.

DEP® The platform's technological advantages are significant.Potential Therapeutic and Commercial Value Includes:

• Enhance efficacy

• Improve Drug Bioavailability

• Reduce Toxic Side Effects

• Prolong the duration of drug action in the body

• Achieve targeted delivery of drugs to specific organs, tissues, or molecular receptors

• Enhance Drug Solubility

DEP® Drug Delivery Platform

Starpharma has built an innovative DEP® oncology drug R&D pipeline. Its clinical-stage assets includeDEP® cabazitaxel, DEP® docetaxel, and DEP® irinotecan, these are dendritic versions of commonly used chemotherapy drugs, inShowed potential for improved efficacy and tolerability in Phase II clinical trials.

In addition, the company has also laid out plans during the R&D phase.DEP® RadiopharmaceuticalsAnd DEP® ADCAwaiting candidate products.

End

---

Statement:All articles published on this official account (including original and reprinted articles) are intended to convey more information, with sources and authors clearly indicated. This official account welcomes sharing in friend circles or large groups.Reproduction in any form by media or institutions without authorization is prohibited.。

Reprint/Business/Contribution| Contact WeChat15618157102（sum_Gmi）

Business Cooperation

Call for Papers

Click to learn more

Previous Review

Review of Innovative Drugs Mid-Term: A New Starting Point After the Bubble Burst

BD Decade Review: Trends and Logic Insights of Cross-border Pharmaceutical Companies' Deals

Industry Watch: Why Are Layoffs Still Sweeping the Biopharmaceutical Sector?